ArticleExperimental and therapeutic medicine2012
Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma.
Article in Experimental and therapeutic medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Review
- Proteomic Profiling Reveals TPR and FGA as Predictive Serum Biomarkers of Relapse to First- and Second-Generation EGFR-TKIs in Advanced Lung Adenocarcinoma.Biomedicines · 2025Article
- Fibrinogen Alpha Chain as a Potential Serum Biomarker for Predicting Response to Cisplatin and Gemcitabine Doublet Chemotherapy in Lung Adenocarcinoma: Integrative Transcriptome and Proteome Analyses.International journal of molecular sciences · 2025Article
- In search of new stratification strategies: tissue proteomic profiling of papillary thyroid microcarcinoma in patients with localized disease and lateral neck metastases.Journal of cancer research and clinical oncology · 2023Article
- Review
- Serum proteome profiling reveals SOX3 as a candidate prognostic marker for gastric cancer.Journal of cellular and molecular medicine · 2020Article
- Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.International journal of molecular sciences · 2019Review
- Proteomic Analysis of Cerebrospinal Fluid From Patients With Extranodal NK-/T-Cell Lymphoma of Nasal-Type With Ethmoidal Sinus Metastasis.Frontiers in oncology · 2019Article
- Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer.Clinical proteomics · 2018Article
- Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests.Scientific reports · 2016Article
- Identification of carboxyl terminal peptide of Fibrinogen as a potential serum biomarker for gastric cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Emerging blood-based biomarkers for detection of gastric cancer.World journal of gastroenterology · 2015Review
- Identification of serum proteome signatures of locally advanced and metastatic gastric cancer: a pilot study.Journal of translational medicine · 2015Article
- Comparative evaluation of 5-15-kDa salivary proteins from patients with different oral diseases by MALDI-TOF/TOF mass spectrometry.Clinical oral investigations · 2015Article
- eRF3b, a biomarker for hepatocellular carcinoma, influences cell cycle and phosphoralation status of 4E-BP1.PloS one · 2014Article
- Potential serum biomarkers for glioblastoma diagnostic assessed by proteomic approaches.Proteome science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to screen for possible serum biomarkers for gastric adenocarcinoma. Surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS) was used to screen serum samples from 109 cases of gastric adenocarcinoma and 106 control subjects (60 healthy subjects, 30 patients with chronic superficial gastritis and 16 cases of chronic atrophic gastritis). The differentially expressed protein peaks were selected and isolated using high performance liquid chromatography (HPLC) and processed with enzyme prior to liquid chromatography-mass spectrometry tandem mass spectrometry (LC-MS/MS) analysis and data mining with software XCalibur program components BioWorks 3.2. Among the gastric cancer cases, three differentially expressed protein peaks were selected as potential serum biomarkers: the m/z peaks at 5,906.5 showed increased expression (8.53±4.33 in the cancer group, and 0.88±0.31 in the control group); the m/z peaks at 6,635.7 and 8,716.3 showed decreased expression (6.54±2.44 and 0.93±0.29, respectively, in the cancer group and 17.56±4.43 and 2.16±0.98, respectively, in the control group) (P<0.01). The m/z peaks at 5,906.5, 6,635.7 and 8,716.3, were identified as fibrinogen α-chain, apolipo-protein A-II and apolipoprotein C-I. The combined use of the three biomarkers distinguished the cancer group patients from the control group samples at a sensitivity of 93.85% (61/65) and a specificity of 94.34% (50/53). In conclusion, fibrinogen α-chain, apolipoprotein A-II and apolipoprotein C-I were identified as potential markers for gastric cancer and appear to have diagnostic value for clinical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.